- Home
- COOT vs IBIO Comparison
COOT vs IBIO Comparison
Compare COOT & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COOT
- IBIO
- Stock Information
- Founded
- COOT 2020
- IBIO 2008
- Country
- COOT Australia
- IBIO United States
- Employees
- COOT N/A
- IBIO N/A
- Industry
- COOT
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- COOT
- IBIO Health Care
- Exchange
- COOT NYSE
- IBIO Nasdaq
- Market Cap
- COOT 23.0M
- IBIO 24.3M
- IPO Year
- COOT N/A
- IBIO N/A
- Fundamental
- Price
- COOT $1.25
- IBIO $3.48
- Analyst Decision
- COOT
- IBIO Strong Buy
- Analyst Count
- COOT 0
- IBIO 3
- Target Price
- COOT N/A
- IBIO $4.87
- AVG Volume (30 Days)
- COOT 14.6K
- IBIO 299.1K
- Earning Date
- COOT 01-01-0001
- IBIO 02-10-2025
- Dividend Yield
- COOT N/A
- IBIO N/A
- EPS Growth
- COOT N/A
- IBIO N/A
- EPS
- COOT N/A
- IBIO N/A
- Revenue
- COOT $23,793,673.00
- IBIO $375,000.00
- Revenue This Year
- COOT N/A
- IBIO $36.00
- Revenue Next Year
- COOT N/A
- IBIO $33.33
- P/E Ratio
- COOT N/A
- IBIO N/A
- Revenue Growth
- COOT 16.10
- IBIO 650.00
- 52 Week Low
- COOT $0.61
- IBIO $1.05
- 52 Week High
- COOT $10.00
- IBIO $4.98
- Technical
- Relative Strength Index (RSI)
- COOT 46.64
- IBIO 55.25
- Support Level
- COOT $1.22
- IBIO $3.22
- Resistance Level
- COOT $1.57
- IBIO $3.76
- Average True Range (ATR)
- COOT 0.14
- IBIO 0.38
- MACD
- COOT -0.01
- IBIO 0.00
- Stochastic Oscillator
- COOT 27.48
- IBIO 56.41
About COOT AUSTRALIAN OILSEEDS HOLDINGS LTD
Australian Oilseeds Holdings Ltd through its subsidiaries, is focused on the manufacture and sale of chemical-free, non-GMO, sustainable edible oils and products derived from oilseeds. The company believes that transitioning from a fossil fuel economy to a renewable and chemical-free economy is the solution to many health problems the world is facing presently.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.